InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
Recent Articles
RELATED ARTICLES
-
HBM gets health boost from drug licensing deals
2142.HK -
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Akeso marks profit milestone with swift rights issue
9926.HK
- Funding boost gets Sunho Biologics over the IPO filing line
-
Everest reaches new heights on growing drug sales
1952.HK
-
With no cure in sight, drugs firm LianBio begins exit strategy
LIAN.US
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
